22 results
424B3
CTCX
Carmell Corp - Ordinary Shares
5 Jun 24
Prospectus supplement
6:06am
research and development products, including those in clinical trials and those that may advance into clinical trials, may not have favorable results … approval for our research and development products because of their status as combination products.
We have conducted and may in the future conduct
8-K/A
EX-99.2
zxeflee vud7xswgu
25 Oct 23
Unaudited Condensed Financial Statements
4:02pm
8-K/A
EX-99.3
2ez5tsjrj5f 3uy
25 Oct 23
Unaudited Condensed Financial Statements
4:02pm
8-K/A
EX-99.1
h8cech3j
25 Oct 23
Unaudited Condensed Financial Statements
4:02pm
8-K/A
EX-99.3
py89ml hjkbzb5t29
14 Aug 23
Completion of Acquisition or Disposition of Assets
5:55pm
8-K/A
EX-99.1
pb5 rtq0bn
14 Aug 23
Completion of Acquisition or Disposition of Assets
5:55pm
8-K/A
EX-99.2
2svdli 8jec6
14 Aug 23
Completion of Acquisition or Disposition of Assets
5:55pm
8-K
EX-10.1
7jqsjpbuo 4sfq
1 Aug 23
Carmell Therapeutics Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company
4:39pm
8-K
EX-99.1
sm1icz
20 Jul 23
Entry into a Material Definitive Agreement
5:21pm
8-K
dwdqqz9
20 Jul 23
Entry into a Material Definitive Agreement
5:21pm
424B3
ryqmx
23 Jun 23
Prospectus supplement
4:47pm